1. Home
  2. AGBK vs PHVS Comparison

AGBK vs PHVS Comparison

Compare AGBK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGBK

AGI Inc Class A Common Shares

N/A

Current Price

$9.89

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.97

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGBK
PHVS
Founded
1999
2015
Country
Brazil
Switzerland
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AGBK
PHVS
Price
$9.89
$26.97
Analyst Decision
Strong Buy
Buy
Analyst Count
5
10
Target Price
$17.20
$40.70
AVG Volume (30 Days)
524.5K
101.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.64
N/A
P/E Ratio
$46.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.00
$11.51
52 Week High
$12.21
$29.80

Technical Indicators

Market Signals
Indicator
AGBK
PHVS
Relative Strength Index (RSI) 38.95 51.12
Support Level $9.00 $24.25
Resistance Level $12.12 $28.90
Average True Range (ATR) 0.52 1.21
MACD -0.20 -0.06
Stochastic Oscillator 28.48 54.90

Price Performance

Historical Comparison
AGBK
PHVS

About AGBK AGI Inc Class A Common Shares

AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: